Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis

• Egile Nagusiak: Alexey K. Petrovsky (Egilea), Nikolay A. Smirnov (Egilea), Vladimir P. Vdovichenko (Egilea), Tatiana B. Fedorova (Egilea), Edgar E. Kerbenev (Egilea), Vladimir N. Fedorov (Egilea)
• Formatua: Liburua
• Argitaratua: Belgorod National Research University, 2019-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: Drug-induced hepatitis is common in clinical practice. This problem is particularly relevant in the treatment of tuberculous infection, because for this purpose, up to 5-6 hepatotoxic drugs are used simultaneously for a long time, which often (in 15-20% of cases) leads to medical liver...